Corporate Profile Media

One Response to “Implant Sciences (IMSC) Expands Global Presence With Sale to Romania”

1. 

   admin
   

   23. May, 2012

   Implant Sciences Expands Global Presence With Sale to Romania

   Company’s Investment in Distribution Channel Continues to Pay Dividends

   WILMINGTON, MA–(Marketwire -05/22/12)- Implant Sciences Corporation (IMSC.PK) (IMSC.PK), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has sold 10 units of its Quantum Sniffer™ QS-H150 handheld explosives trace detector to a customer in Romania. The units will be deployed in several applications to help ensure the security of this European nation.

   This is the first sale of Implant Sciences’ systems by Romanian-based distributor Business Plus, a provider of logistics, security, operational, and safety equipment. Business Plus has served aviation, law enforcement, and military users since 2003.

   “We are pleased to announce the success of our Romanian distributor, Business Plus, in securing this key order and we are proud that our technology will be utilized to fulfill the security needs of their customer,” stated Implant Sciences’ President and CEO, Glenn D. Bolduc. “Countries throughout the world are facing persistent and increasing threats from IEDs (Improvised Explosive Devices). The operational and cost advantages of our technology continue to drive purchasing decisions in our favor.”

   About the Quantum Sniffer™ QS-H150

   The QS-H150 is a handheld explosives trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. The QS-H150 uses no radioactive materials and features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

   About Implant Sciences

   Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences’ QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company’s QS-B220 bench-top explosives and narcotics trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company’s website at http://www.implantsciences.com

   Safe Harbor Statement

   This press release may contain certain “forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and are subject to risks and uncertainties that could cause the Company’s actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management’s current expectations and assumptions which could differ materially from the forward-looking statements.